Janux Therapeutics (JANX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

JANX Stock Forecast


Janux Therapeutics stock forecast is as follows: an average price target of $70.25 (represents a 25.13% upside from JANX’s last price of $56.14) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

JANX Price Target


The average price target for Janux Therapeutics (JANX) is $70.25 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $42.00. This represents a potential 25.13% upside from JANX's last price of $56.14.

JANX Analyst Ratings


Buy

According to 4 Wall Street analysts, Janux Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for JANX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Janux Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 03, 2024Justin ZelinBTIG$100.00$40.18148.88%78.13%
Oct 24, 2024David DaiUBS$69.00$51.7533.33%22.91%
Sep 05, 2024Bradley CaninoStifel Nicolaus$70.00$43.7160.15%24.69%
Aug 09, 2024George FarmerScotiabank$42.00$36.4915.10%-25.19%
May 30, 2024George FarmerScotiabank$47.00$47.60-1.26%-16.28%
May 13, 2024Swayampakula RamakanthH.C. Wainwright$63.00$49.6326.94%12.22%
Mar 20, 2024Kaveri PohlmanBTIG$62.00$39.1358.45%10.44%

The latest Janux Therapeutics stock forecast, released on Dec 03, 2024 by Justin Zelin from BTIG, set a price target of $100.00, which represents a 148.88% increase from the stock price at the time of the forecast ($40.18), and a 78.13% increase from JANX last price ($56.14).

Janux Therapeutics Price Target by Period


1M3M12M
# Anlaysts127
Avg Price Target$100.00$84.50$64.71
Last Closing Price$56.14$56.14$56.14
Upside/Downside78.13%50.52%15.27%

In the current month, the average price target of Janux Therapeutics stock is $100.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 78.13% increase as opposed to Janux Therapeutics's last price of $56.14. This month's average price target is up 18.34% compared to last quarter, and up 54.54% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Dec 03, 2024BTIGBuyBuyHold
Oct 24, 2024WedbushSector PerformSector PerformHold
Oct 24, 2024UBSUnderperformUnderperformHold
Oct 24, 2024UBSBuyInitialise
Sep 06, 2024ScotiabankUnderperformUnderperformHold
Sep 06, 2024WedbushSector PerformSector PerformHold
Aug 09, 2024WedbushSector PerformSector PerformHold
Aug 09, 2024ScotiabankUnderperformUnderperformHold
Aug 09, 2024ScotiabankSector PerformSector PerformHold
May 30, 2024WedbushSector PerformSector PerformHold
May 30, 2024ScotiabankUnderperformUnderperformHold
May 30, 2024ScotiabankSector PerformInitialise
May 13, 2024WedbushBuyBuyHold
May 13, 2024JonesTradingUnderperformUnderperformHold
May 13, 2024H.C. WainwrightBuyBuyHold
Nov 14, 2022William BlairOutperformInitialise

Janux Therapeutics's last stock rating was published by BTIG on Dec 03, 2024. The company gave JANX a "Buy" rating, the same as its previous rate.

Janux Therapeutics Financial Forecast


Janux Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
Revenue-------------$2.52M$1.06M$2.05M$2.85M$1.81M$2.37M$1.59M$1.62M$1.16M$482.00K
Avg Forecast$705.40K$669.19K$634.84K$602.25K$277.78K$277.78K$222.22K$222.22K$1.15M$1.50M$772.00K$878.57K$750.00K$845.50K$875.00K$672.35K$805.50K$742.58K$650.00K$810.40K$433.33K$133.33K$133.33K
High Forecast$705.40K$669.19K$634.84K$602.25K$277.78K$277.78K$222.22K$222.22K$1.15M$1.50M$772.00K$878.78K$811.22K$845.75K$875.00K$672.35K$805.50K$742.58K$650.00K$810.40K$433.33K$133.33K$133.33K
Low Forecast$705.40K$669.19K$634.84K$602.25K$277.78K$277.78K$222.22K$222.22K$1.15M$1.50M$772.00K$878.36K$688.77K$845.25K$875.00K$672.35K$805.50K$742.58K$650.00K$810.40K$433.33K$133.33K$133.33K
# Analysts644643791011131111111111
Surprise %-------------2.98%1.21%3.05%3.53%2.44%3.64%1.96%3.73%8.69%3.62%

Janux Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $750.00K, with a low forecast of $688.77K, and a high forecast of $811.22K. JANX's average Quarter revenue forecast represents a -70.20% decrease compared to the company's last Quarter revenue of $2.52M (Sep 23).

Janux Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts644643791011131111111111
EBITDA-------------$-15.81M$-20.75M$-20.28M$-18.27M$-17.77M$-17.15M$-13.46M$-13.42M$-10.74M$-6.19M
Avg Forecast$-141.08K$-133.84K$-126.97K$-120.45K$-55.55K$-55.55K$-44.44K$-44.44K$-230.27K$-299.04K$-154.40K$-175.71K$-150.00K$-169.10K$-175.00K$-134.47K$-161.10K$-148.52K$-130.00K$-14.98M$-86.67K$-26.67K$-17.65M
High Forecast$-141.08K$-133.84K$-126.97K$-120.45K$-55.55K$-55.55K$-44.44K$-44.44K$-230.27K$-299.04K$-154.40K$-175.67K$-137.75K$-169.05K$-175.00K$-134.47K$-161.10K$-148.52K$-130.00K$-11.98M$-86.67K$-26.67K$-14.12M
Low Forecast$-141.08K$-133.84K$-126.97K$-120.45K$-55.55K$-55.55K$-44.44K$-44.44K$-230.27K$-299.04K$-154.40K$-175.76K$-162.24K$-169.15K$-175.00K$-134.47K$-161.10K$-148.52K$-130.00K$-17.98M$-86.67K$-26.67K$-21.18M
Surprise %-------------93.51%118.56%150.82%113.38%119.67%131.95%0.90%154.80%402.72%0.35%

undefined analysts predict JANX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Janux Therapeutics's previous annual EBITDA (undefined) of $NaN.

Janux Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts644643791011131111111111
Net Income-------------$-11.57M$-17.51M$-14.18M$-11.26M$-14.04M$-16.52M$-13.15M$-13.34M$-10.77M$-6.21M
Avg Forecast$-23.51M$-20.25M$-18.83M$-17.73M$-31.94M$-27.61M$-24.65M$-22.01M$-23.30M$-17.88M$-16.97M$-18.10M$-22.68M$-25.68M$-27.42M$-26.55M$-26.29M$-25.46M$-17.24M$-15.22M$-14.70M$-9.62M$-17.69M
High Forecast$-23.51M$-20.25M$-18.83M$-17.73M$-31.94M$-27.61M$-24.65M$-15.41M$-17.73M$-17.88M$-16.97M$-18.10M$-18.39M$-25.68M$-27.42M$-26.55M$-26.29M$-25.46M$-17.24M$-12.18M$-14.70M$-9.62M$-14.15M
Low Forecast$-23.51M$-20.25M$-18.83M$-17.73M$-31.94M$-27.61M$-24.65M$-32.13M$-30.90M$-17.88M$-16.97M$-18.10M$-25.75M$-25.68M$-27.42M$-26.55M$-26.29M$-25.46M$-17.24M$-18.27M$-14.70M$-9.62M$-21.22M
Surprise %-------------0.45%0.64%0.53%0.43%0.55%0.96%0.86%0.91%1.12%0.35%

Janux Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. JANX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Janux Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts644643791011131111111111
SG&A-------------$6.44M$6.88M$6.46M$5.68M$6.10M$5.54M$4.95M$3.94M$3.66M$2.00M
Avg Forecast$1.50M$1.43M$1.35M$1.28M$592.16K$592.16K$473.73K$473.73K$2.45M$3.19M$1.65M$1.87M$1.60M$1.80M$1.87M$1.43M$1.72M$1.58M$1.39M$1.73M$923.77K$284.24K$284.24K
High Forecast$1.50M$1.43M$1.35M$1.28M$592.16K$592.16K$473.73K$473.73K$2.45M$3.19M$1.65M$1.87M$1.73M$1.80M$1.87M$1.43M$1.72M$1.58M$1.39M$1.73M$923.77K$284.24K$284.24K
Low Forecast$1.50M$1.43M$1.35M$1.28M$592.16K$592.16K$473.73K$473.73K$2.45M$3.19M$1.65M$1.87M$1.47M$1.80M$1.87M$1.43M$1.72M$1.58M$1.39M$1.73M$923.77K$284.24K$284.24K
Surprise %-------------3.57%3.69%4.51%3.31%3.85%4.00%2.86%4.26%12.86%7.03%

Janux Therapeutics's average Quarter SG&A projection for Dec 23 is $1.60M, based on 3 Wall Street analysts, with a range of $1.47M to $1.73M. The forecast indicates a -75.17% fall compared to JANX last annual SG&A of $6.44M (Sep 23).

Janux Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts644643791011131111111111
EPS-------------$-0.25$-0.42$-0.34$-0.27$-0.34$-0.40$-0.32$-0.32$-0.26$-0.62
Avg Forecast$-0.43$-0.37$-0.34$-0.32$-0.58$-0.51$-0.45$-0.40$-0.43$-0.33$-0.31$-0.33$-0.42$-0.47$-0.50$-0.49$-0.48$-0.47$-0.32$-0.32$-0.27$-0.18$-0.14
High Forecast$-0.43$-0.37$-0.34$-0.32$-0.58$-0.51$-0.45$-0.28$-0.32$-0.33$-0.31$-0.33$-0.34$-0.47$-0.50$-0.49$-0.48$-0.47$-0.32$-0.32$-0.27$-0.18$-0.14
Low Forecast$-0.43$-0.37$-0.34$-0.32$-0.58$-0.51$-0.45$-0.59$-0.57$-0.33$-0.31$-0.33$-0.47$-0.47$-0.50$-0.49$-0.48$-0.47$-0.32$-0.32$-0.27$-0.18$-0.14
Surprise %-------------0.53%0.84%0.70%0.56%0.73%1.26%1.00%1.19%1.47%4.43%

According to undefined Wall Street analysts, Janux Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to JANX previous annual EPS of $NaN (undefined).

Janux Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
KROSKeros Therapeutics$16.71$101.00504.43%Buy
MOLNMolecular Partners$5.31$29.00446.14%Buy
AVTEAerovate Therapeutics$2.60$13.00400.00%Hold
ANEBAnebulo Pharmaceuticals$1.62$6.00270.37%Buy
ANTXAN2 Therapeutics$1.36$5.00267.65%Buy
ACRVAcrivon Therapeutics$6.23$22.50261.16%Buy
ADAGAdagene$1.94$5.00157.73%Buy
FENCFennec Pharmaceuticals$6.19$15.75154.44%Buy
MLYSMineralys Therapeutics$12.80$30.00134.38%Buy
EWTXEdgewise Therapeutics$29.62$46.2556.14%Buy
RZLTRezolute$4.41$6.6751.25%Buy
HRMYHarmony Biosciences$34.06$45.3333.09%Buy
JANXJanux Therapeutics$56.14$70.2525.13%Buy

JANX Forecast FAQ


Is Janux Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Janux Therapeutics (JANX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of JANX's total ratings.

What is JANX's price target?

Janux Therapeutics (JANX) average price target is $70.25 with a range of $42 to $100, implying a 25.13% from its last price of $56.14. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Janux Therapeutics stock go up soon?

According to Wall Street analysts' prediction for JANX stock, the company can go up by 25.13% (from the last price of $56.14 to the average price target of $70.25), up by 78.13% based on the highest stock price target, and down by -25.19% based on the lowest stock price target.

Can Janux Therapeutics stock reach $80?

JANX's highest twelve months analyst stock price target of $100 supports the claim that Janux Therapeutics can reach $80 in the near future.

What is Janux Therapeutics's current price target trend?

1 Wall Street analyst forecast a $100 price target for Janux Therapeutics (JANX) this month, up 78.13% from its last price of $56.14. Compared to the last 3 and 12 months, the average price target increased by 50.52% and increased by 15.27%, respectively.

What are Janux Therapeutics's analysts' financial forecasts?

Janux Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1M (high $1M, low $1M), average EBITDA is $-200K (high $-200K, low $-200K), average net income is $-106M (high $-99.602M, low $-116M), average SG&A $2.13M (high $2.13M, low $2.13M), and average EPS is $-1.944 (high $-1.823, low $-2.129). JANX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.61M (high $2.61M, low $2.61M), average EBITDA is $-522K (high $-522K, low $-522K), average net income is $-80.315M (high $-80.315M, low $-80.315M), average SG&A $5.57M (high $5.57M, low $5.57M), and average EPS is $-1.47 (high $-1.47, low $-1.47).

Did the JANX's actual financial results beat the analysts' financial forecasts?

Based on Janux Therapeutics's last annual report (Dec 2023), the company's revenue was $8.08M, beating the average analysts forecast of $3.14M by 157.19%. Apple's EBITDA was $-72.979M, beating the average prediction of $-629K by 11510.40%. The company's net income was $-58.293M, missing the average estimation of $-102M by -43.03%. Apple's SG&A was $26.14M, beating the average forecast of $6.7M by 290.16%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.873 by -99.93%. In terms of the last quarterly report (Sep 2023), Janux Therapeutics's revenue was $2.52M, beating the average analysts' forecast of $845.5K by 197.69%. The company's EBITDA was $-15.813M, beating the average prediction of $-169K by 9251.33%. Janux Therapeutics's net income was $-11.568M, missing the average estimation of $-25.675M by -54.95%. The company's SG&A was $6.44M, beating the average forecast of $1.8M by 257.19%. Lastly, the company's EPS was $-0.25, missing the average prediction of $-0.47 by -46.81%